CapyFin

Calendar Reports

Search for a symbol...

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2026 CapyFin. All rights reserved.

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

Edgewise Therapeutics Fiscal Q4 2024 Earnings Report - CapyFin

Edgewise Therapeutics

EWTX · NASDAQ🇺🇸

Overview Earnings

Dividends Seasonality Metrics

Q3 2025 -1.67%Q2 2025 -4.08%Q1 2025 +2.36%Q4 2024 -2.45%Q3 2024 -0.66%Q2 2024 +3.59%Q1 2024 -12.25%Q4 2023 -1.26%Q3 2023 -10.70%Q2 2023 +3.39%Q1 2023 -6.46%Q4 2022 -3.04%Q3 2022 +1.81%Q2 2022 +15.98%Q1 2022 +1.63%Q4 2021 +13.04%Q3 2021 -1.82%Q2 2021 -5.61%Q1 2021 +5.24%Q4 2020 +5.24%Q3 2020 Q2 2020 Q1 2020

Mar 03, 2025

•

Dec 31, 2024

Edgewise Therapeutics Q4 2024 Earnings Report

Edgewise Therapeutics reported fourth quarter and full year 2024 financial results and provided recent business highlights.

Key Takeaways

Edgewise Therapeutics reported positive Phase 2 CANYON results, completed enrollment in GRAND CANYON, and advanced CIRRUS-HCM in Q4 2024. The company's cash, cash equivalents, and marketable securities were approximately $470.2 million as of December 31, 2024.

Completed enrollment of the GRAND CANYON global pivotal study of sevasemten in Becker muscular dystrophy.

Announced positive top-line results from Phase 2 CANYON trial of sevasemten in Becker.

On track to report data from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy in the first quarter of 2025.

On track to report data from the Phase 2 LYNX and FOX trials of sevasemten in Duchenne muscular dystrophy in the first half of 2025.

Previous year: $2.25M

Previous year: -$0.47

Previous year: $1.72M

Cash and Equivalents

Previous year: $318M

Previous year: -$27M

Previous year: $340M

Edgewise Therapeutics

Unlock previous datapoints

Edgewise Therapeutics

Unlock previous datapoints

Forward Guidance

Edgewise Therapeutics anticipates several milestones in 2025, including data readouts from ongoing clinical trials and regulatory interactions.

Positive Outlook

Reporting data from Phase 2 CIRRUS-HCM trial of EDG-7500 in HCM in Q1 2025.
Reporting data from Phase 2 LYNX and FOX trials of sevasemten in Duchenne in the first half of 2025.
Engaging the U.S. FDA in the first half of 2025 to discuss marketing authorization filing strategies for sevasemten in Becker.
Filing an investigational new drug application for a novel candidate for the treatment of heart failure during 2025.
Selecting a proprietary cardiometabolic drug candidate based on preclinical proof-of-concept data during 2025.

Challenges Ahead

Potential risks associated with product candidates causing serious adverse events.
Uncertainties related to regulatory approval processes.
Risks related to reliance on third-party manufacturers.

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Company Overview

Full financial data and analysis

View Edgewise Therapeutics

Risks related to not achieving adequate market acceptance.

Dependence on the success of sevasemten and EDG-7500.